Log in

NASDAQ:CDTX - Cidara Therapeutics Stock Price, Forecast & News

$3.16
0.00 (0.00 %)
(As of 02/21/2020 04:00 PM ET)
Today's Range
$3.08
Now: $3.16
$3.24
50-Day Range
$2.92
MA: $3.34
$4.26
52-Week Range
$1.22
Now: $3.16
$4.44
Volume154,314 shs
Average Volume397,794 shs
Market Capitalization$104.41 million
P/E RatioN/A
Dividend YieldN/A
Beta2.34
Cidara Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-infectives for the treatment of diseases. Its lead product candidate is rezafungin acetate, a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CDTX
CUSIPN/A
Phone858-752-6170

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.13 per share

Profitability

Net Income$-59,020,000.00

Miscellaneous

Employees68
Market Cap$104.41 million
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive CDTX News and Ratings via Email

Sign-up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter.


Cidara Therapeutics (NASDAQ:CDTX) Frequently Asked Questions

What is Cidara Therapeutics' stock symbol?

Cidara Therapeutics trades on the NASDAQ under the ticker symbol "CDTX."

How were Cidara Therapeutics' earnings last quarter?

Cidara Therapeutics Inc (NASDAQ:CDTX) posted its earnings results on Thursday, November, 7th. The biotechnology company reported $0.08 earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.34. The biotechnology company earned $19.10 million during the quarter, compared to analyst estimates of $30 million. View Cidara Therapeutics' Earnings History.

When is Cidara Therapeutics' next earnings date?

Cidara Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Cidara Therapeutics.

What price target have analysts set for CDTX?

6 brokerages have issued 1-year price objectives for Cidara Therapeutics' shares. Their forecasts range from $4.00 to $10.00. On average, they expect Cidara Therapeutics' share price to reach $6.88 in the next twelve months. This suggests a possible upside of 117.6% from the stock's current price. View Analyst Price Targets for Cidara Therapeutics.

What is the consensus analysts' recommendation for Cidara Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cidara Therapeutics in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cidara Therapeutics.

What are Wall Street analysts saying about Cidara Therapeutics stock?

Here are some recent quotes from research analysts about Cidara Therapeutics stock:
  • 1. According to Zacks Investment Research, "Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California. " (1/22/2020)
  • 2. Cantor Fitzgerald analysts commented, "CDTX’s pipeline is focused on better ways to treat fungal and bacterial infections as well as influenza. We expect pipeline advancements to drive upwards earnings revisions to levels not yet reflected in the consensus. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $15." (4/15/2019)

Has Cidara Therapeutics been receiving favorable news coverage?

Media headlines about CDTX stock have trended very negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cidara Therapeutics earned a news sentiment score of -3.4 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Cidara Therapeutics.

Are investors shorting Cidara Therapeutics?

Cidara Therapeutics saw a drop in short interest during the month of January. As of January 31st, there was short interest totalling 1,230,000 shares, a drop of 7.5% from the January 15th total of 1,330,000 shares. Based on an average daily volume of 303,900 shares, the short-interest ratio is currently 4.0 days. Approximately 6.0% of the company's stock are short sold. View Cidara Therapeutics' Current Options Chain.

Who are some of Cidara Therapeutics' key competitors?

What other stocks do shareholders of Cidara Therapeutics own?

Who are Cidara Therapeutics' key executives?

Cidara Therapeutics' management team includes the folowing people:
  • Dr. Jeffrey L. Stein, Pres, CEO & Exec. Director (Age 64)
  • Dr. Taylor Sandison, Chief Medical Officer (Age 47)
  • Dr. Kevin M. Forrest Ph.D., Founder and Chief Strategy Officer (Age 42)
  • Mr. James E. Levine, Chief Financial Officer (Age 48)
  • Mr. Paul Daruwala, COO & Chief Commercial Officer (Age 50)

When did Cidara Therapeutics IPO?

(CDTX) raised $60 million in an initial public offering on Wednesday, April 15th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers.

Who are Cidara Therapeutics' major shareholders?

Cidara Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include 5AM Venture Management LLC (6.07%), Renaissance Technologies LLC (2.41%), Bank of Montreal Can (0.54%), Oxford Asset Management LLP (0.52%), Jacobs Levy Equity Management Inc. (0.44%) and Raymond James Financial Services Advisors Inc. (0.38%). Company insiders that own Cidara Therapeutics stock include James E Levine, Jeffrey Stein, Jessica Oien, Neil Abdollahian and Paul Daruwala. View Institutional Ownership Trends for Cidara Therapeutics.

Which major investors are selling Cidara Therapeutics stock?

CDTX stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc.. Company insiders that have sold Cidara Therapeutics company stock in the last year include Jessica Oien, Neil Abdollahian and Paul Daruwala. View Insider Buying and Selling for Cidara Therapeutics.

Which major investors are buying Cidara Therapeutics stock?

CDTX stock was bought by a variety of institutional investors in the last quarter, including 5AM Venture Management LLC, Bank of Montreal Can, Oxford Asset Management LLP, Jacobs Levy Equity Management Inc., Renaissance Technologies LLC, Acadian Asset Management LLC, Banco Bilbao Vizcaya Argentaria S.A. and Marshall Wace LLP. Company insiders that have bought Cidara Therapeutics stock in the last two years include James E Levine and Jeffrey Stein. View Insider Buying and Selling for Cidara Therapeutics.

How do I buy shares of Cidara Therapeutics?

Shares of CDTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cidara Therapeutics' stock price today?

One share of CDTX stock can currently be purchased for approximately $3.16.

How big of a company is Cidara Therapeutics?

Cidara Therapeutics has a market capitalization of $104.41 million. The biotechnology company earns $-59,020,000.00 in net income (profit) each year or ($2.32) on an earnings per share basis. Cidara Therapeutics employs 68 workers across the globe.View Additional Information About Cidara Therapeutics.

What is Cidara Therapeutics' official website?

The official website for Cidara Therapeutics is http://www.cidara.com/.

How can I contact Cidara Therapeutics?

Cidara Therapeutics' mailing address is 6310 NANCY RIDGE DRIVE SUITE 101, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-752-6170 or via email at [email protected]


MarketBeat Community Rating for Cidara Therapeutics (NASDAQ CDTX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  364 (Vote Outperform)
Underperform Votes:  277 (Vote Underperform)
Total Votes:  641
MarketBeat's community ratings are surveys of what our community members think about Cidara Therapeutics and other stocks. Vote "Outperform" if you believe CDTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2020 by MarketBeat.com Staff

Featured Article: What is a stock buyback?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel